Peptech Limited
12Patents
0Active
12Granted
30Portfolio score
Filing activity: Dec 19, 1997 → Mar 25, 2004
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6448380B2 | Tumor necrosis factor antibodies | Chemistry; Metallurgy | 115 | Expired |
| US6498237B2 | Tumor necrosis factor antibodies | Chemistry; Metallurgy | 114 | Expired |
| US6451983B2 | Tumor necrosis factor antibodies | Chemistry; Metallurgy | 114 | Expired |
| US6593458B1 | Tumor necrosis factor peptide binding antibodies | Chemistry; Metallurgy | 92 | Expired |
| US6924309B2 | Anti-inflammatory nitro and thia-fatty acids | Emerging Cross-Sectional Technologies | 28 | Expired |
| US6337318B1 | Sustained GnRH peptide-release formulation | Human Necessities | 18 | Expired |
| US6913761B1 | Bioimplant formulation | Human Necessities | 10 | Expired |
| US5925619A | Formulation for peptide release | Human Necessities | 6 | Expired |
| US6777386B2 | Sustained peptide-release formulation | Human Necessities | 5 | Expired |
| US7309689B2 | Sustained peptide-release formulation | Human Necessities | 4 | Expired |
| US6375928B1 | Neutrophil stimulating peptides | Emerging Cross-Sectional Technologies | 3 | Expired |
| US6211152A | Formulations for peptide release | Human Necessities | 2 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.